Nano Drug Delivery System, 2nd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (20 December 2023) | Viewed by 2947

Special Issue Editor

Department of Biotechnology, College of Life Science, CHA University, Gyeonggi 13488, Republic of Korea
Interests: nanomaterial; drug delivery; nano biosensor; plasmonic
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Over the past few decades, a variety of approches for efficient drug delivery systems have been developed via targeting, increasing bioavailability, as well by improving the pharmacological profile of drugs. In particular, the application of nanomaterials as drug carriers or nanodelivery systems has brought significant advancenents in the field of drug delivery research. For example, the design of smart functional nanocarriers in drug delivery systems for therapeutic application is attracting an ever-increasing amount of attention for use in targeted treatments and controlled releases.

Researchers are invited to submit articles to this Special Issue to provide up-to-date insights into the smart and advanced drug delivery nanosystems which are improving therapeutic efficiency.

Dr. Surin Hong
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery
  • nanocarriers
  • nanosystem
  • nanomedicine

Related Special Issue

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

26 pages, 2763 KiB  
Review
Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research
by Youngbo Choi, Youbeen Choi and Surin Hong
Pharmaceutics 2024, 16(2), 221; https://doi.org/10.3390/pharmaceutics16020221 - 03 Feb 2024
Viewed by 1333
Abstract
Antibody–drug conjugate (ADC) therapy, an advanced therapeutic technology comprising antibodies, chemical linkers, and cytotoxic payloads, addresses the limitations of traditional chemotherapy. This study explores key elements of ADC therapy, focusing on antibody development, linker design, and cytotoxic payload delivery. The global rise in [...] Read more.
Antibody–drug conjugate (ADC) therapy, an advanced therapeutic technology comprising antibodies, chemical linkers, and cytotoxic payloads, addresses the limitations of traditional chemotherapy. This study explores key elements of ADC therapy, focusing on antibody development, linker design, and cytotoxic payload delivery. The global rise in cancer incidence has driven increased investment in anticancer agents, resulting in significant growth in the ADC therapy market. Over the past two decades, notable progress has been made, with approvals for 14 ADC treatments targeting various cancers by 2022. Diverse ADC therapies for hematologic malignancies and solid tumors have emerged, with numerous candidates currently undergoing clinical trials. Recent years have seen a noteworthy increase in ADC therapy clinical trials, marked by the initiation of numerous new therapies in 2022. Research and development, coupled with patent applications, have intensified, notably from major companies like Pfizer Inc. (New York, NY, USA), AbbVie Pharmaceuticals Inc. (USA), Regeneron Pharmaceuticals Inc. (Tarrytown, NY, USA), and Seagen Inc. (Bothell, WA, USA). While ADC therapy holds great promise in anticancer treatment, challenges persist, including premature payload release and immune-related side effects. Ongoing research and innovation are crucial for advancing ADC therapy. Future developments may include novel conjugation methods, stable linker designs, efficient payload delivery technologies, and integration with nanotechnology, driving the evolution of ADC therapy in anticancer treatment. Full article
(This article belongs to the Special Issue Nano Drug Delivery System, 2nd Edition)
Show Figures

Figure 1

41 pages, 8778 KiB  
Review
Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections
by Yutong Guo, Zeyuan Mao, Fang Ran, Jihong Sun, Jingfeng Zhang, Guihong Chai and Jian Wang
Pharmaceutics 2023, 15(11), 2582; https://doi.org/10.3390/pharmaceutics15112582 - 03 Nov 2023
Cited by 2 | Viewed by 1298
Abstract
Airway mucus dysfunction and impaired immunological defenses are hallmarks of several lung diseases, including asthma, cystic fibrosis, and chronic obstructive pulmonary diseases, and are mostly causative factors in bacterial-biofilm-associated respiratory tract infections. Bacteria residing within the biofilm architecture pose a complex challenge in [...] Read more.
Airway mucus dysfunction and impaired immunological defenses are hallmarks of several lung diseases, including asthma, cystic fibrosis, and chronic obstructive pulmonary diseases, and are mostly causative factors in bacterial-biofilm-associated respiratory tract infections. Bacteria residing within the biofilm architecture pose a complex challenge in clinical settings due to their increased tolerance to currently available antibiotics and host immune responses, resulting in chronic infections with high recalcitrance and high rates of morbidity and mortality. To address these unmet clinical needs, potential anti-biofilm therapeutic strategies are being developed to effectively control bacterial biofilm. This review focuses on recent advances in the development and application of nanoparticulate drug delivery systems for the treatment of biofilm-associated respiratory tract infections, especially addressing the respiratory barriers of concern for biofilm accessibility and the various types of nanoparticles used to combat biofilms. Understanding the obstacles facing pulmonary drug delivery to bacterial biofilms and nanoparticle-based approaches to combatting biofilm may encourage researchers to explore promising treatment modalities for bacterial-biofilm-associated chronic lung infections. Full article
(This article belongs to the Special Issue Nano Drug Delivery System, 2nd Edition)
Show Figures

Figure 1

Back to TopTop